Shares of Amedisys Inc (NASDAQ:AMED) have earned an average rating of “Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $107.08.
Several equities research analysts have recently commented on the stock. ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 28th. UBS Group assumed coverage on shares of Amedisys in a report on Friday, November 16th. They issued a “neutral” rating and a $126.00 price target for the company. Bank of America set a $139.00 price target on shares of Amedisys and gave the company a “buy” rating in a report on Tuesday, September 18th. Cantor Fitzgerald assumed coverage on shares of Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price target for the company. Finally, Canaccord Genuity assumed coverage on shares of Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price target for the company.
In other news, CFO Scott G. Ginn sold 7,640 shares of Amedisys stock in a transaction that occurred on Monday, November 12th. The shares were sold at an average price of $117.41, for a total value of $897,012.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total transaction of $48,440.58. Following the completion of the transaction, the insider now directly owns 11,818 shares in the company, valued at approximately $1,438,368.78. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,486 shares of company stock valued at $4,449,649. Company insiders own 2.60% of the company’s stock.
AMED traded down $0.32 on Friday, reaching $135.93. 104,269 shares of the company traded hands, compared to its average volume of 540,570. Amedisys has a one year low of $49.80 and a one year high of $138.50. The firm has a market capitalization of $4.34 billion, a price-to-earnings ratio of 61.51, a PEG ratio of 2.03 and a beta of 1.28. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Monday, October 29th. The health services provider reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.18. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The company had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. During the same quarter last year, the business posted $0.56 EPS. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. On average, equities analysts anticipate that Amedisys will post 3.58 earnings per share for the current fiscal year.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Further Reading: Swap
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.